Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oommen John

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
Intensive Care Medicine|November 10, 2021
Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trialAnders Granholm, Marie Warrer Munch, Sheila Nainan Myatra, et al.
Acta Anaesthesiologica Scandinavica|February 14, 2021
Higher vs Lower Doses of Dexamethasone in Patients with COVID-19 and Severe Hypoxia (COVID STEROID 2) trial: Protocol for a secondary Bayesian analysisAnders Granholm, Marie Warrer Munch, Sheila Nainan Myatra, et al.
Intensive Care Medicine|April 1, 2022
Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemiaAnders Granholm, Maj-Brit Nørregaard Kjær, Marie Warrer Munch, et al.
JMIR Infodemiology|April 4, 2023
Measuring the Burden of Infodemics: Summary of the Methods and Results of the Fifth WHO Infodemic Management ConferenceElisabeth Wilhelm, Isabella Ballalai, Marie-Eve Belanger, et al.
NEJM Evidence|February 6, 2024
A Randomized Trial of Nafamostat for Covid-19Susan C Morpeth, Balasubramanian Venkatesh, James A Totterdell, et al.
JAMA|October 21, 2021
Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial, Marie W Munch, Sheila N Myatra, et al.
NEJM Evidence|February 6, 2024
Anticoagulation Strategies in Non-Critically Ill Patients with Covid-19Zoe K McQuilten, Balasubramanian Venkatesh, Vivekanand Jha, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
Intensive Care Medicine|November 10, 2021
Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trialAnders Granholm, Marie Warrer Munch, Sheila Nainan Myatra, et al.
Acta Anaesthesiologica Scandinavica|February 14, 2021
Higher vs Lower Doses of Dexamethasone in Patients with COVID-19 and Severe Hypoxia (COVID STEROID 2) trial: Protocol for a secondary Bayesian analysisAnders Granholm, Marie Warrer Munch, Sheila Nainan Myatra, et al.
Intensive Care Medicine|April 1, 2022
Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemiaAnders Granholm, Maj-Brit Nørregaard Kjær, Marie Warrer Munch, et al.
JMIR Infodemiology|April 4, 2023
Measuring the Burden of Infodemics: Summary of the Methods and Results of the Fifth WHO Infodemic Management ConferenceElisabeth Wilhelm, Isabella Ballalai, Marie-Eve Belanger, et al.
NEJM Evidence|February 6, 2024
A Randomized Trial of Nafamostat for Covid-19Susan C Morpeth, Balasubramanian Venkatesh, James A Totterdell, et al.
JAMA|October 21, 2021
Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial, Marie W Munch, Sheila N Myatra, et al.
NEJM Evidence|February 6, 2024
Anticoagulation Strategies in Non-Critically Ill Patients with Covid-19Zoe K McQuilten, Balasubramanian Venkatesh, Vivekanand Jha, et al.
Pageof 7